Drug Trial Radar · NCT06926621
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
44
Planned (sponsor's estimate)
Start
Apr 28, 2025
Primary completion
Jan 30, 2029
Study completion Jan 30, 2029
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Apr 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).
Conditions
- Myotonic Dystrophy Type 1 (DM1)
Interventions
VX-670Drug
Solution for intravenous administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 up to Week 108
Locations
16 sites in 8 countries. Site status is shown where the registry gives one.
St. Louis Children's Hospital - Neurology
St Louis, Missouri
Wake Forest Univ School of Medicine - Neurology
Winston-Salem, North Carolina
Virginia Commonwealth University - Sanger Hall
Richmond, Virginia
Wesley Research Institute
Auchenflower, Australia
Neuroscience Clinical Trials Unit, Alfred Brain
Melbourne, Australia
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Pulmonology
Leuven, Belgium
Altasciences Montreal
Montreal, Canada
Montreal Neurological Institute-Hospital
Montreal, Canada
University of Ottawa
Ottawa, Canada
Universite Laval - Neurology
Québec, Canada
Friedrich Baur Institute
München, Germany
Maastricht UMC
Maastricht, Netherlands
Hospital Universitario y Politecnico La Fe - Neurology
Valencia, Spain
Queen Elizabeth University Hospital - Neurology
Glasgow, United Kingdom
Leonard Wolfson Experimental Neurology Centre CRF
London, United Kingdom
Royal Hallamshire Hospital - Neurology
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.